Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species

被引:66
作者
Gerson, Julia E. [1 ]
Castillo-Carranza, Diana L. [1 ]
Kayed, Rakez [1 ]
机构
[1] Univ Texas Med Branch, Dept Neurol, George & Cynthia Mitchell Ctr Alzheimers Dis Res, Galveston, TX 77555 USA
来源
ACS CHEMICAL NEUROSCIENCE | 2014年 / 5卷 / 09期
关键词
Oligomers; immunotherapy; molecular chaperones; small molecules; PAIRED HELICAL FILAMENTS; NUCLEATED CONFORMATIONAL CONVERSION; MICROTUBULE-STABILIZING AGENT; HEAT-SHOCK PROTEINS; ALZHEIMERS-DISEASE; MOUSE MODEL; AMYLOID-BETA; IN-VITRO; A-BETA; METHYLENE-BLUE;
D O I
10.1021/cn500143n
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurodegenerative disease is one of the greatest health concerns today and with no effective treatment in sight, it is crucial that researchers find a safe and successful therapeutic. While neurofibrillary tangles are considered the primary tauopathy hallmark, more evidence continues to come to light to suggest that soluble, intermediate tau aggregates tau oligomers-are the most toxic species in disease. These intermediate tau species may also be responsible for the spread of pathology, suggesting that oligomeric tau may be the best therapeutic target. Here, we summarize results for the modulation of tau by molecular chaperones, small molecules and aggregation inhibitors, post-translational modifications, immunotherapy, other techniques, and future directions.
引用
收藏
页码:752 / 769
页数:18
相关论文
共 271 条
[11]  
[Anonymous], 2009, ALZHEIMERS DEMENT, DOI [DOI 10.1016/J.JALZ.2009.04.925, 10.1016/j.jalz.2009.04.925]
[12]  
[Anonymous], SCIENTIFICA
[13]   A non-toxic Hsp90 inhibitor protects neurons from Aβ-induced toxicity [J].
Ansar, Sabah ;
Burlison, Joseph A. ;
Hadden, M. Kyle ;
Yu, Xiao Ming ;
Desino, Kelly E. ;
Bean, Jennifer ;
Neckers, Len ;
Audus, Ken L. ;
Michaelis, Mary L. ;
Blagg, Brian S. J. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (07) :1984-1990
[14]   Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements [J].
Asuni, Ayodeji A. ;
Boutajangout, Allal ;
Quartermain, David ;
Sigurdsson, Einar M. .
JOURNAL OF NEUROSCIENCE, 2007, 27 (34) :9115-9129
[15]   The specificities of protein kinase inhibitors: an update [J].
Bain, J ;
McLauchlan, H ;
Elliott, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2003, 371 :199-204
[16]   Tau-mediated neurodegeneration in Alzheimer's disease and related disorders [J].
Ballatore, Carlo ;
Lee, Virginia M. -Y. ;
Trojanowski, John Q. .
NATURE REVIEWS NEUROSCIENCE, 2007, 8 (09) :663-672
[17]   Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties [J].
Ballatore, Carlo ;
Crowe, Alex ;
Piscitelli, Francesco ;
James, Michael ;
Lou, Kevin ;
Rossidivito, Gabrielle ;
Yao, Yuemang ;
Trojanowski, John Q. ;
Lee, Virginia M-Y ;
Brunden, Kurt R. ;
Smith, Amos B., III .
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (14) :4451-4461
[18]   Discovery of Brain-Penetrant, Orally Bioavailable Aminothienopyridazine Inhibitors of Tau Aggregation [J].
Ballatore, Carlo ;
Brunden, Kurt R. ;
Piscitelli, Francesco ;
James, Michael J. ;
Crowe, Alex ;
Yao, Yuemang ;
Hyde, Edward ;
Trojanowski, John Q. ;
Lee, Virginia M. -Y. ;
Smith, Amos B., III .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (09) :3739-3747
[19]  
Ballinger CA, 1999, MOL CELL BIOL, V19, P4535
[20]   Toward a unified scheme for the aggregation of tau into Alzheimer paired helical filaments [J].
Barghorn, S ;
Mandelkow, E .
BIOCHEMISTRY, 2002, 41 (50) :14885-14896